🧪 Beta — BiohacksAI is under active development. Data and features may change.
B
BiohacksAI
Evidence-Based Biohacking
BetaPatent Pending

MAP4K3

MOLECULAR TARGET

mitogen-activated protein kinase kinase kinase kinase 3

UniProt: Q8IVH8NCBI Gene: 849142 compounds

MAP4K3 (mitogen-activated protein kinase kinase kinase kinase 3) is targeted by 42 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MAP4K3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1alvocidib4.5291
2foretinib4.3476
3tozasertib4.3375
4vandetanib4.3073
5bosutinib4.0858
6midostaurin3.8546
7pazopanib3.6939
8neratinib3.6638
9nintedanib3.6136
10pelitinib3.5032
11tae 6843.4330
12fedratinib3.4029
13gilteritinib3.4029
14linifanib3.3327
15dovitinib3.0921
16jnj 77066213.0921
17lestaurtinib3.0420
18pf 037583093.0019
19ruboxistaurin2.9418
20danusertib2.9418
21r 4062.8316
22k 252a2.8316
23cediranib2.8316
24milciclib2.7715
25capivasertib2.7715
26pha 6657522.7114
27crenolanib2.7114
28kw 24492.6413
29linsitinib2.6413
30ast 4872.5612
31zotiraciclib2.5612
32raf 2652.4811
33ripasudil2.4010
34azd 77622.309
35su 0148132.208
36cyc 1162.087
37Crizotinib1.795
38pf 038147351.795
39ucn 011.795
40osi 6321.795
41Axitinib0.691
42Dasatinib0.691

About MAP4K3 as a Drug Target

MAP4K3 (mitogen-activated protein kinase kinase kinase kinase 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 42 compounds with documented MAP4K3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MAP4K3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.